Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 7, 2009
Tue, October 6, 2009 VTPK and CHTP Have Been Added To Naked Short Lists Today
October 6, 2009 /M2 PRESSWIRE/ BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold lists. Vertigo Theme Parks (OTC: VTPK) and Chelsea Therapeutics (NASDAQ: CHTP). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Vertigo Theme Parks, Inc. (OTC: VTPK) operates as a theme park company. The companya�s aVertigo Parka� is a premier park, which features Adrenaline Rush Adventures. Vertigo Park is located just outside of Cali at Club Estancia de la Plaz in Buga-Quebrasa Seca Valle Del Cauca, Colombia. Vertigo Park would include Arab-Dubai style Shopping Center that serves as the entrance featuring shopping, outlet bargain stores, restaurants, Movie Theater, arcades and would offer festivities on a daily basis. The park would feature Vertigo Force, a launch Coaster with a track approximately 8,000 feet and reaching heights of approximately 300 feet installed through canyons already staged as the geography of the site. The Coaster would have 4 cars that carry 12 passengers each, leaving the station every 35 seconds. There would be additional Coasters within the park as well as rides for children of all ages. The Park would also offer sections of Fantasy, Animal Shows, Horse Shows, Dancing, Special Feature Presentations, Gaming, Musical Events and Reality Shows. The Park would present a theme style atmosphere with flavors of Andalusia, Spain. The park is under construction. Strategic Alliance The company has completed a Strategic Business Alliance with Industria Nacional de Gaseosas S.A. (Industria) one of four bottling companies owned by Coca-Cola FEMSA S.A.B. de C.V. in Colombia. Industria distributes promotional materials for the park to its approximately 370,000 value added retailers throughout Colombia. Industria would also distribute promotional materials through its relationships with movie theaters, fast food restaurants, and pharmacies. There is a failure to deliver in shares of VTPK.
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinsona�s disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial. The company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus. Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. There is a failure to deliver in shares of CHTP.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2.650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO / www.BUYINS.net / (800) 715-9999 / tom@buyins.net
